Helping patients reclaim a life of possibility
On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible for evaluating medicines and making recommendations on whether they should be approved for use…
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…
Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the first Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation (EUHTAR). The statement was coordinated by the European Patients Forum (EPF) and welcomes…
On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first…
At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the…
The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is…
Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland (NI). Myeloma Forward will hold bi-monthly meetings where speakers talk about some aspect of living with myeloma and share experiences and stories, providing peer support…
MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria. Plasma donations are needed from people to produce immunoglobulin replacement therapy (you might hear it called IVIG) which is used in myeloma to reduce the risk of infection. It is of interest to MPE because myeloma…